a Objectives: The objectives of this study were to determine HIV drug resistance (HIVDR) prevalence in Zambian infants upon diagnosis, and to determine how changing prevention of mother-to-child transmission (PMTCT) drug regimens affect drug resistance.
Introduction
Antiretrovirals (ARVs), specifically prevention of motherto-child transmission (PMTCT), have reduced perinatal HIV transmission rate from 15-45% to less than 5% [1, 2] . Even in resource-limited countries like Zambia, where limited access to ARVs and suboptimal adherence increase the risk of mother-to-child transmission, transmission dropped from 24% in 2009 to 13% in 2014 [3] . Despite these successes, when PMTCT fails, exposure of the mother or child to ARVs can select for drug resistance HIV transmitted from the mother or arise de novo after transmission [4, 5] . Young children infected with HIV are at an increased risk of developing drug resistance because of their immature immune responses. In addition, maternal lack of adherence, dosing difficulties because of variable infant pharmacokinetics, changing body weight, and poorly formulated pediatric formulations can also result in reduced ARV efficacy [6] [7] [8] [9] .
The WHO PMTCT guidelines have undergone changes in accord with the availability of more potent drugs, and PMTCT drug regimens in Zambia have evolved. In 2006, mothers and infants were given a single dose of the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) [10] . In 2010 a version of WHO option A [11] was adopted. The maternal regimen consisting of the nucleoside reverse transcriptase inhibitor (NRTI) zidovudine (AZT) was given at 28 weeks of gestation; NVP and Combivir (Brentford, UK) (AZTand 3TC) at delivery and Combivir was continued for 1 week postpartum. Infants received NVP throughout breastfeeding. In 2013, Option B was implemented, where all women are placed on a three-drug ARV regimen regardless of CD4 þ T-cell count [10, 12] .
Although other studies have sought to define the impact of drug resistance on treatment failure in children [8, 9] , limited information is available about the role PMTCT drug exposure played in the occurrence of resistance in infected infants. Given PMTCT regimen changes in Zambia, it is important to define how these changes were influencing drug resistance. To clarify correlations between PMTCT regimens and resistance in infants, we sequenced the HIV-1 reverse transcriptase region from Zambian infants, stratified over three distinct PMTCT regimens. Both the prevalence and the magnitude of drug resistance increased in Zambian infants from 2007 to 2014. Additionally, infants with reported PMTCT participation showed stronger and more frequent resistance than those without ARV exposure.
Materials and methods
Discarded dried blood spots (DBS) of infants used for routine HIV-1 screening were obtained from the University Teaching Hospital in Lusaka, Zambia. DNA was extracted from DBS using a detergent lysis with proteinase K digestion method, followed by phenolchloroform extraction. The reverse transcriptase region was amplified by nested PCR as described previously [13] . Amplification of 1493 bp products was confirmed by gel electrophoresis and purified using E. Sequence data from all five primers were trimmed and a contig was generated in BioEdit v7.2.5 for each study participant. Patient contigs were analyzed using the Stanford drug resistance database (http://hivdb.standford. edu), which also provided an overall drug resistance score.
A two-sided t-test was used to test for significance in mean drug resistance score using Prism 5 (GraphPad, San Diego, CA, USA).
Results

Cohort characteristics
Samples analyzed were from the Lusaka District and were selected randomly. (Fig. 1a) . The prevalence of dual class resistance (at least one mutation to both an NRTI and NNRTI) increased from less than 2% of infants in both 2007-2009 and 2011 to over 10% in 2014 (Fig. 1a) .
To investigate the strength of the resistance conferred, drug resistance scores as provided by the database were compared between groups. A higher drug resistance score signifies stronger resistance. Figure 1b shows the drug resistance score for each infant by group, along with the mean and 95% confidence interval. Children with no measurable resistance (a score of 0) were not included in the analysis. Average drug resistance scores were 64. (Fig. 1b) . There was no significant difference between the average scores in 2011 and 2014 (P ¼ 0.2). Together, our findings suggest that the prevalence of drug resistance and the strength of resistance conferred both increased temporally.
Prevention of mother-to-child transmission and drug resistance Because the dataset from 2014 comprised the largest number of samples, exhibited the highest resistance, and contained the best descriptive data, it was used to investigate the potential role of PMTCT in drug resistance. There was a significant increase in both the prevalence and strength of resistance in infants with PMTCT exposure (Fig. 2a and b ). Infants were considered PMTCTexposed HIV drug resistance Poppe et al. 1887 Infants where either the mother or child reported receiving PMTCT were classified as exposed, whereas those in which neither the mother nor the child reported receiving PMTCT were considered unexposed. NNRTI, nonnucleoside reverse transcriptase inhibitor, NRTI, nucleoside reverse transcriptase inhibitor, PMTCT, prevention of mother-to-child transmission.
if either the mother or child received ARVs for prophylaxis or mother received HIV treatment, while those that did not receive any ARVs at this pregnancy were considered unexposed. Of the 82 samples in the 2014 group, 48 were PMTCT exposed and 30 were unexposed; PMTCT information was unavailable for the remaining four. A higher percentage of infants involved in PMTCT had drug resistance, regardless of class, compared with those without PTMCT, with overall resistance rates of 54% and 20%, respectively (Fig. 2a) . No PMTCT unexposed infants had dual-class resistance, but all exposed infants with NRTI resistance also had NNRTI resistance. PMTCT exposed infants had a significantly higher mean drug resistance score of 128.3 compared with unexposed at 30.3 (P ¼ 0.004, Fig. 2b ). Importantly, 20% of infants with no reported PMTCTexposure still showed drug resistance ( Fig. 2a) with several displaying modest drug resistance scores (Fig. 2b) . No correlation was observed between drug resistance and the age of the infant at time of sampling (1 day to 15 months, median 4 months), sex (45.7% men), or current breastfeeding status (69.6% currently breastfeeding).
Discussion
From 2007 to 2014, total HIV drug resistance (HIVDR) increased from 21% to 40% in Zambian infants. Strength of drug resistance also increased. Every infant with NNRTI resistance showed resistance to NVP. The most prevalent mutation in 2014, Y181C, confers high-level resistance to NVP, consistent with its prevalence in studies from South Africa [14] and Tanzania [15] . As over onethird of infants in this study possessed high-NVP resistance, our data support the current practice of using protease inhibitor-based drug regimens as first-line treatment in children previously exposed to NVP.
Our results showed that 10-fold more infants in the 2014 group displayed dual-class resistance, and twice as many had NRTI resistance than in other groups. Interestingly, these increases correlate with changes in the PMTCT regimen. The prolonged NRTI use during breastfeeding in 2014 compared to 2011 likely contributed to the increased resistance, as it has been shown that NRTIs were detectable in breast milk and selected for drug resistance in the child [4, 16] . However, the limited information available for these samples did not allow the establishment of a correlation between duration of breastfeeding and NRTI resistance.
Among 2014 samples with available clinical information, infants with PMTCT exposure had a higher prevalence and significantly stronger drug resistance than those without, which is consistent with other studies from the region [14, 17] . However, we did not find a correlation between the age and prevalence of drug resistance [14] . As in prior studies, some children with no reported PMTCT exposure still had resistance, indicating a direct transmission of resistant viruses from mother-to-child had occurred [14, 17] . We were unable to determine if resistance originated in the mother or arose de novo in the infant.
Our data suggest increases in both the prevalence and strength of HIVDR in Zambia, where 40% infants sampled in 2014 showed some resistance, have the potential to present serious complications for HIV-1 treatment. The increased resistance corresponds to changes in treatment regimens; however, resistance was detected in infected children with no previous ARV exposure through PMTCT, suggesting the circulation of ARV-resistant strains in the general Zambian population. Further studies are needed to determine whether mutations are transmitted from the mother or develop in the child, as well as how long they persist. Knowledge gained from such future studies will allow for the development of strategies to further reduce HIV transmission and the development of drug resistance.
